Hsbc Holdings PLC Has $203,000 Holdings in Xencor, Inc. (NASDAQ:XNCR)

Hsbc Holdings PLC trimmed its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 17.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,750 shares of the biopharmaceutical company’s stock after selling 2,266 shares during the period. Hsbc Holdings PLC’s holdings in Xencor were worth $203,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Parallel Advisors LLC grew its holdings in shares of Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,015 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Xencor by 153.7% in the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,316 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Xencor in the second quarter valued at $154,000. Acadian Asset Management LLC acquired a new stake in Xencor in the first quarter valued at $206,000. Finally, Los Angeles Capital Management LLC bought a new position in Xencor during the 1st quarter worth $229,000.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. JPMorgan Chase & Co. reduced their price objective on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Xencor in a research note on Monday, September 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research report on Tuesday, August 6th. Finally, Raymond James lowered their target price on Xencor from $58.00 to $40.00 and set a “strong-buy” rating on the stock in a research report on Friday, June 14th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.78.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 36,329 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $665,547.28. Following the completion of the sale, the vice president now owns 192,319 shares in the company, valued at approximately $3,523,284.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.23% of the company’s stock.

Xencor Stock Performance

NASDAQ XNCR opened at $19.85 on Friday. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $26.84. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -9.06 and a beta of 0.67. The company has a fifty day moving average price of $18.55 and a 200-day moving average price of $20.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.

Xencor (NASDAQ:XNCR) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The business had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. Xencor’s quarterly revenue was down 62.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.37) EPS. As a group, equities research analysts predict that Xencor, Inc. will post -4.15 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.